1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Tibet Cheezheng Tibetan Medicine Co., Ltd. Class A

Tibet Cheezheng Tibetan Medicine Co., Ltd. Class A

SSZSE:002287
19.31
CNY
+0.29
(+1.52%)
1.58EPS
11.92P/E
10.78BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.85
1.82
1.89
1.84
2
2.3
2.65
2.81
3.35
3.86
3.86
4.41
4.45
4.75
Basic EPS, GAAP
0.41
0.45
0.5
0.55
0.57
0.6
0.69
0.76
1.35
0.89
1.1
1.1
1.19
1.58
Free Cash Flow per Basic Share
0.24
0.44
0.37
0.4
0.31
0.7
0.67
-0.19
1.72
0.03
0.87
0.38
1.06
- -
Dividend per Share
0.24
0.27
0.3
0.32
0.31
0.33
0.32
0.37
0.37
0.64
0.42
0.53
0.83
0.44
Book Value per Share
2.67
2.85
3.06
3.29
3.56
3.85
4.24
4.94
5.98
6.29
7.02
7.65
8.65
8.91
Tangible Book Value per Share
2.53
2.69
2.89
3.19
3.47
3.76
4.15
4.61
5.22
5.58
6.35
7.04
8.12
8.4
Basic Weighted Avg Shares
523
523
527
527
527
527
528
529
529
530
530
530
544
556
Sales/Revenue/Turnover
969
950
995
968
1,053
1,213
1,403
1,485
1,770
2,045
2,045
2,338
2,416
2,643
Operating Margin (%)
23.13
24.72
25.23
25.99
29.88
26.44
26.27
28.42
28.12
29.43
30.96
26.16
30.2
36.47
Depreciation Expense
24
25
33
30
23
23
36
44
66
83
93
139
142
- -
Net Income, GAAP
213
238
265
290
301
319
364
404
716
473
581
582
648
879
Effective Tax Rate (%)
18.12
17.69
10.3
8.28
7.18
9.39
9.19
9.17
9.78
9.55
10.12
10.04
12.48
11.77
Profit Margin (%)
22.01
25
26.63
29.93
28.57
26.27
25.97
27.2
40.43
23.11
28.42
24.91
26.84
33.25
Working Capital
1,125
1,181
1,041
1,128
1,219
1,287
1,481
2,202
1,628
1,832
1,949
2,490
2,630
2,635
LT Debt
- -
- -
- -
- -
- -
- -
- -
911
841
934
1,068
799
7
28
Total Equity
1,448
1,550
1,651
1,751
1,894
2,045
2,262
2,635
3,220
3,388
3,770
4,113
4,996
5,145
Return on Invested Capital (%)
12.98
12.79
14.44
13.68
14.92
15.27
15.59
12.75
16.58
9.59
11.02
10.49
11.33
14.84
Return on Capital (%)
14.75
15.78
16.15
16.16
15.3
15.8
15.99
13.21
18.03
10.79
12.32
11.43
11.69
15.04
Return on Common Equity (%)
15.63
16.31
17.01
17.33
16.66
16.32
17.04
16.61
24.74
14.53
16.47
14.96
14.39
19.28

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
923
777
889
LT Borrowings
3
28
25
LT Finance Leases
3
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
572
572
572
Market Capitalization
13,536
13,153
10,779

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,308
4,067
3,963
Cash, Cash Equivalents & STI
2,948
2,655
2,849
Accounts Receivable, Net
100
242
377
Inventories
294
340
329
Total Current Liabilities
1,679
1,305
1,327
Payables & Accruals
- -
- -
- -
ST Debt
923
777
889
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.85%
13.85%
21.45%
Free Cash Flow
236.83%
477.71%
186.44%
Net Income, GAAP
12.21%
15.55%
11.36%
Sales/Revenue/Turnover
9.52%
10.48%
3.34%
Total Cash Common Dividend
15.07%
25.75%
60.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
365
645
462
866
2,338
2025
403
772
- -
893
2,416
2026
405
573
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.43
0.13
0.36
1.1
2025
0.14
0.53
- -
0.4
1.19
2026
0.17
0.49
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.51
0.01
0.53
2025
0.22
- -
- -
- -
0.83
2026
0.01
0.41
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Haijian Xia
Full Time Employees
3,203
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 2, Deji Road Nyingchi TB China 860000
IPO Date
Sep 9, 2009
Website
cheezheng.com.cn
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) engages in the research, development, production, and sale of Tibetan medicines in China. The company offers a range of products including emplastrum such as Cheezheng Xiaotong pain relieving plaster; ointments including Qingpeng Ointment and Baimai Ointment (White Veil Ointment); granules and capsules such as Shiwei Gentian flower granules and capsules, Renqing Mangjue capsules; oral medicines including Ruyi Jumbo tablets and Safflower Ruyi pills; and crude drugs, targeting orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, cerebrovascular, musculoskeletal, digestive, urinary, and reproductive systems. It distributes these products primarily within the domestic Chinese market with limited overseas sales to regions including the United States, Canada, Hong Kong, Malaysia, Singapore, and South America. Founded in 1995 and headquartered in Nyingchi, Tibet Autonomous Region, China, the company operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd. and maintains 22 wholly-owned and holding subsidiaries, including GMP-certified pharmaceutical factories and GSP marketing firms, employing approximately 3,170 people. In recent developments, the company announced an equity buyback plan in March 2025 for up to CNY 160 million, with tranche updates through July 2025; reported earnings for the half-year ended June 30, 2025 in July; and approved an external investment project at its board meeting on July 31, 2025, funded by internal resources over a two-year construction period.